PF-03654746

DRUG5 trials

Sponsors

Pfizer

Conditions

Allergic RhinitisAlzheimer's DiseaseAttention Deficit Hyperactivity DisorderExcessive Daytime SleepinessNarcolepsyTourette's Syndrome

Phase 1

A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

TerminatedNCT01028911

PfizerAlzheimer's Disease

Start: 2009-12-31End: 2010-05-31Updated: 2014-06-04

Phase 2

A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

CompletedNCT00531752

PfizerAttention Deficit Hyperactivity Disorder

Start: 2007-12-31End: 2008-09-30Updated: 2016-02-19

A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge

CompletedNCT00562120

PfizerAllergic Rhinitis

Start: 2007-12-31End: 2008-08-31Updated: 2014-04-16

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

CompletedNCT01006122

PfizerExcessive Daytime Sleepiness, Narcolepsy

Start: 2009-11-30End: 2010-11-30Updated: 2014-05-09

Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome

WithdrawnNCT01475383

PfizerTourette's Syndrome

Start: 2012-04-30End: 2012-04-30Updated: 2019-04-01